AMPHOTERICIN-B LIPID COMPLEX TO TREAT INVASIVE FUNGAL-INFECTIONS IN CANCER-PATIENTS - REPORT OF EFFICACY AND SAFETY IN 20 PATIENTS

被引：18

作者：

ORAVCOVA, E

MISTRIK, M

SAKALOVA, A

DRGONA, L

KOLLAR, T

HELPIANSKA, L

ILAVSKA, I

SORKOVSKA, D

SPANIK, S

KUKUCKOVA, E

KRCMERY, V

机构：

[1] UNIV TRNAVA,DEPT CLIN MED,BRATISLAVA,SLOVAKIA

[2] COMENIUS UNIV BRATISLAVA,POSTGRAD MED SCH,DEPT CHEMOTHERAPY,BRATISLAVA,SLOVAKIA

[3] COMENIUS UNIV BRATISLAVA,SCH MED,NATL CANC CTR,DEPT MED,BRATISLAVA,SLOVAKIA

[4] COMENIUS UNIV BRATISLAVA,SCH MED,NATL CANC CTR,DEPT HEMATOL,BRATISLAVA,SLOVAKIA

[5] COMENIUS UNIV BRATISLAVA,SCH MED,DEPT ONCOL,BRATISLAVA,SLOVAKIA

来源：

CHEMOTHERAPY | 1995年 / 41卷 / 06期

关键词：

AMPHOTERICIN B LIPID COMPLEX; INFECTION; FUNGAL;

D O I：

10.1159/000239385

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

20 patients with proven or suspected fungal infections were treated with the amphotericin B lipid complex (ABLC) with a daily dose of 5 mg/kg for 1-25 days. 6 patients died during the therapy due to fungal infection (3) or underlying disease (3). One patient was not evaluable. 13 patients were cured and improved. ABLC was administered in patients with renal disese avoiding the use of conventional amphotericin B (AmB) because of nephrotoxicity or after failure with AmB. Except for hypokalemia persisting after AmB in 5 patients, no systemic adverse reaction appeared. ABLC is a promising, well-tolerated and effective drug for the therapy of fungal infections after the failure of a previous antifungal therapy or after toxic reactions due to AmB.

引用

页码：473 / 476

页数：4

共 50 条

[31] RECENT DEVELOPMENTS IN PROPHYLAXIS AND THERAPY OF INVASIVE FUNGAL-INFECTIONS IN GRANULOCYTOPENIC CANCER-PATIENTS
MEUNIER, F
KLASTERSKY, J
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (03): : 539 - 544
[32] Amphotericin B lipid complex for the treatment of invasive fungal infections
Linden, PK
EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (11) : 2099 - 2110
[33] PRIMARY CUTANEOUS OPPORTUNISTIC FUNGAL-INFECTIONS IN CANCER-PATIENTS
KHARDORI, N
HAYAT, S
ROLSTON, KVI
BODEY, GP
CLINICAL RESEARCH, 1988, 36 (06): : A847 - A847
[34] FUNGAL-INFECTIONS IN CANCER-PATIENTS - AN INTERNATIONAL AUTOPSY SURVEY
BODEY, G
BUELTMANN, B
DUGUID, W
GIBBS, D
HANAK, H
HOTCHI, M
MALL, G
MARTINO, P
MEUNIER, F
MILLIKEN, S
NAOE, S
OKUDAIRA, M
SCEVOLA, D
VANTWOUT, J
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1992, 11 (02) : 99 - 109
[35] MICONAZOLE THERAPY FOR TREATMENT OF FUNGAL-INFECTIONS IN CANCER-PATIENTS
JORDAN, WM
BODEY, GP
RODRIGUEZ, V
KETCHEL, SJ
HENNEY, J
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1979, 16 (06) : 792 - 797
[36] SYSTEMIC FUNGAL-INFECTIONS IN CANCER-PATIENTS - RECENT UPDATE
MAKSYMIUK, AW
THONGPRASERT, S
BODEY, GP
BLUMENSCHEIN, GR
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 443 - 443
[37] PROPHYLAXIS OF FUNGAL-INFECTIONS WITH ITRACONAZOLE IN IMMUNOCOMPROMISED CANCER-PATIENTS
MUHLDORFER, SM
KONIG, HJ
MYCOSES, 1990, 33 (06) : 291 - 295
[38] BUDGET IMPACT ANALYSIS OF LIPOSOMAL AMPHOTERICIN B AND AMPHOTERICIN B LIPID COMPLEX FOR TREATING INVASIVE FUNGAL INFECTIONS IN HOSPITALIZED PATIENTS
Chaudhari, P.
Yang, H.
Zhou, Z. Y.
Patel, C.
Wu, E. Q.
VALUE IN HEALTH, 2013, 16 (03) : A83 - A84
[39] Efficacy and toxicity of amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients after allogenic stem cell transplantion
Langebrake, C.
Bendig, C.
Zabelina, T.
Lellek, H.
Zander, A. R.
Kroeger, N.
ONKOLOGIE, 2010, 33 : 69 - 69
[40] LOW INCIDENCE OF INVASIVE FUNGAL-INFECTIONS AFTER BONE-MARROW TRANSPLANTATION IN PATIENTS RECEIVING AMPHOTERICIN-B INHALATIONS DURING NEUTROPENIA
HERTENSTEIN, B
STEFANIC, M
NOVOTNY, J
KERN, WV
BUNJES, D
HEIMPEL, H
SCHMEISER, T
WIESNETH, M
ARNOLD, R
ANNALS OF HEMATOLOGY, 1994, 68 (01) : 21 - 26

← 1 2 3 4 5 →